James L Gajewski

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Impending challenges in the hematopoietic stem cell transplantation physician workforce
    James L Gajewski
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon 97239, USA
    Biol Blood Marrow Transplant 15:1493-501. 2009
  2. ncbi A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
    James L Gajewski
    Department of Medicine, Temple University, Philadelphia, PA, USA
    Blood 112:3036-47. 2008
  3. ncbi Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation
    Baldeep Wirk
    Fox Chase Temple University BMT Program, Temple University School of Medicine, 7604 Central Avenue, Philadelphia, PA 19111, USA
    Transfusion 48:163-8. 2008
  4. ncbi Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Cancer 106:2327-36. 2006
  5. ncbi The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation services
    James L Gajewski
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 11:871-80. 2005
  6. ncbi The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy
    Yee Chung Cheng
    Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:794-804. 2004
  7. ncbi Blood and marrow transplantation compensation: perspective in payer and provider relations
    James L Gajewski
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Biol Blood Marrow Transplant 10:427-32. 2004
  8. ncbi Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
    Raymond Wong
    Department of Blood and Marrow Transplantation, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:3052-9. 2003
  9. ncbi Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
  10. ncbi Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002

Collaborators

  • Claudio Anasetti
  • Richard T Maziarz
  • S Gerald Sandler
  • Naoto T Ueno
  • M L Donato
  • Chitra Hosing
  • Issa F Khouri
  • E H Estey
  • Richard E Champlin
  • Baldeep Wirk
  • Emer O Hanrahan
  • Gabriel N Hortobagyi
  • Aman U Buzdar
  • Yee Chung Cheng
  • Terry L Smith
  • Raymond Wong
  • Filippo Montemurro
  • Mary E Martin
  • Jay H Herman
  • Kenneth F Mangan
  • Thomas R Klumpp
  • John Ulicny
  • Robert V B Emmons
  • Vicente Valero
  • Sonja E Singletary
  • Eric A Strom
  • Kristine Broglio
  • Deborah Frye
  • Daniel J Booser
  • Richard L Theriault
  • Elizabeth J Shpall
  • Ying Yang
  • Roy Jones
  • Munir Shahjahan
  • Mark Munsell
  • Thomas Martin
  • Cindy Ippoliti
  • John McMannis
  • Daniel R Couriel
  • Borje S Andersson
  • Zia U Rahman
  • Pedro Cano
  • Athanasios Anagnostopoulos
  • Sergio A Giralt
  • Marcos de Lima

Detail Information

Publications10

  1. ncbi Impending challenges in the hematopoietic stem cell transplantation physician workforce
    James L Gajewski
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon 97239, USA
    Biol Blood Marrow Transplant 15:1493-501. 2009
    ....
  2. ncbi A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
    James L Gajewski
    Department of Medicine, Temple University, Philadelphia, PA, USA
    Blood 112:3036-47. 2008
    ....
  3. ncbi Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation
    Baldeep Wirk
    Fox Chase Temple University BMT Program, Temple University School of Medicine, 7604 Central Avenue, Philadelphia, PA 19111, USA
    Transfusion 48:163-8. 2008
    ..This suggests that donor-recipient Rh mismatching is a risk factor in allogeneic hematopoietic stem cell transplantation and should be a criterion for donor selection...
  4. ncbi Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Cancer 106:2327-36. 2006
    ....
  5. ncbi The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation services
    James L Gajewski
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 11:871-80. 2005
    ..Details about the individual codes and their approval process are reviewed in this article...
  6. ncbi The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy
    Yee Chung Cheng
    Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:794-804. 2004
    ..In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting...
  7. ncbi Blood and marrow transplantation compensation: perspective in payer and provider relations
    James L Gajewski
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Biol Blood Marrow Transplant 10:427-32. 2004
    ..Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy...
  8. ncbi Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
    Raymond Wong
    Department of Blood and Marrow Transplantation, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:3052-9. 2003
    ..Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease...
  9. ncbi Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
    ..01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control...
  10. ncbi Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002
    ..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...